Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Placebo-Controlled, Single Dose, Escalating Dose Study to Determine the Safety and Tolerability of Intranasal REVTx-99 in Healthy Adult Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1, Placebo-Controlled, Single Dose, Escalating Dose Study to Determine the Safety and Tolerability of Intranasal REVTx-99 in Healthy Adult Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyranosyl lipid adjuvant (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 11 May 2021 Planned number of patients changed from 32 to 48.
    • 11 May 2021 Status changed from recruiting to completed.
    • 05 May 2021 Primary endpoint (To determine the Safety and Tolerability of a single intranasal dose REVTx-99 when administered to healthy adults as assessed by the collection of safety data, such as adverse events, clinical laboratory tests, vital signs, 12-lead ECGs and Physical Exams.) has been met, according to a Revelation Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top